Plasma Circulating Terminal Differentiation-Induced Non-Coding RNA Serves as a Biomarker in Breast Cancer.

Breast cancer is identified as the most common malignancy and cause of cancer-related death worldwide. Compared with healthy controls, this study evaluated the expression level and diagnostic power of lncRNA plasma in breast cancer patients. Fifty-eight women diagnosed with invasive ductal carcinoma and fifty healthy age- matched controls were included in the study. TRIzol LS regent was used to isolate the total RNA from the whole plasma. Total RNA was converted to cDNA using Prime Script RT reagent kit and the expression levels of were quantified by qRT-PCR. Low levels of lncRNA were observed in the plasma of breast cancer patients compared with control subjects. Plasma level was also positively correlated with the diagnostic age of breast cancer patients. A low level of plasma could discriminate breast cancer patients from healthy control subjects.